Marchex Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marchex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Marchex stock.
View analyst ratings for Marchex or view top-rated stocks.

Wall Street analysts have given Marchex a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Marchex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Marchex is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Marchex.

Marchex, Inc. (NASDAQ:MCHX) announced its earnings results on Thursday, August, 5th. The technology company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.08. The technology company had revenue of $14.01 million for the quarter, compared to the consensus estimate of $13.12 million. Marchex had a negative net margin of 22.26% and a negative trailing twelve-month return on equity of 19.67%.
View Marchex's earnings history.

Marchex's stock was trading at $2.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MCHX stock has increased by 58.2% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19.

2 equities research analysts have issued 12 month target prices for Marchex's stock. Their forecasts range from $4.00 to $4.75. On average, they expect Marchex's share price to reach $4.38 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts' price targets for Marchex or view top-rated stocks among Wall Street analysts.

8 employees have rated Marchex CEO Russell Horowitz, Michael Arends, and Ethan Caldwell. on Glassdoor.com. Russell Horowitz, Michael Arends, and Ethan Caldwell. has an approval rating of 58% among Marchex's employees. This puts Russell Horowitz, Michael Arends, and Ethan Caldwell. in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Marchex include Facebook (FB), SEA (SE), Equinix (EQIX), Twitter (TWTR), eBay (EBAY), CoStar Group (CSGP), VeriSign (VRSN), Akamai Technologies (AKAM), Opendoor Technologies (OPEN), J2 Global (JCOM), Angi (ANGI), Stamps.com (STMP), SPS Commerce (SPSC), LivePerson (LPSN) and Envestnet (ENV).
View all of MCHX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marchex investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Enphase Energy (ENPH), NVIDIA (NVDA), OPKO Health (OPK), Nokia (NOK), Overstock.com (OSTK), Square (SQ) and Zynga (ZNGA).

Marchex trades on the NASDAQ under the ticker symbol "MCHX."

Marchex's stock is owned by many different retail and institutional investors. Top institutional investors include Edenbrook Capital LLC (32.49%), Renaissance Technologies LLC (5.76%), B. Riley Financial Inc. (5.31%), Vanguard Group Inc. (2.44%), BlackRock Inc. (1.57%) and P.A.W. Capital Corp (1.43%). Company insiders that own Marchex stock include Edenbrook Capital, Llc, Jeff Baxter, John Roswech, Long Only Value Fund Edenbrook and Michael A Arends.
View institutional ownership trends for Marchex.

MCHX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., California Public Employees Retirement System, Renaissance Technologies LLC, Stifel Financial Corp, Bridgeway Capital Management LLC, Bank of America Corp DE, and Northern Trust Corp.
View insider buying and selling activity for Marchex or view top insider-selling stocks.

MCHX stock was acquired by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., State Street Corp, Edenbrook Capital LLC, Squarepoint Ops LLC, Ergoteles LLC, Kennedy Capital Management Inc., and Geode Capital Management LLC. Company insiders that have bought Marchex stock in the last two years include Edenbrook Capital, Llc, Jeff Baxter, John Roswech, Long Only Value Fund Edenbrook, and Michael A Arends.
View insider buying and selling activity for Marchex or or view top insider-buying stocks.

Shares of MCHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCHX stock can currently be purchased for approximately $3.18.

Marchex has a market capitalization of $131.70 million and generates $51.22 million in revenue each year. The technology company earns $-38,450,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

Marchex employs 245 workers across the globe.

The following companies are subsidiares of Marchex: Callcap, and Telmetrics.

Marchex was founded in 2003.

The official website for Marchex is www.marchex.com.

Marchex is headquartered at 520 PIKE STREET SUITE 2000, SEATTLE WA, 98101.

Marchex's mailing address is 520 PIKE STREET SUITE 2000, SEATTLE WA, 98101. The technology company can be reached via phone at (206) 331-3300 or via email at [email protected].